Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Naldemedine in Pediatric Patients Receiving Opioids
NCT05588323Phase 2Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of naldemedine in opioid-induced constipation (OIC), sponsored by Shionogi & Co., Ltd.. Started Jan 2023; status: recruiting.
02
Drugs
naldemedine
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT05588323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588323.